首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism
【24h】

Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism

机译:Wnt拮抗剂Dickkopf2参与葡萄糖代谢调控的化学和遗传证据

获取原文
获取原文并翻译 | 示例
       

摘要

Mutations in Wnt receptor LRP5/6 and polymorphism in Wnt-regulated transcription factor TCF7L2 are associated with dysregu-lation of glucose metabolism. However, it is not clear whether Wnt antagonist Dickkopf (Dkk) has a significant role in the regulation of glucose metabolism. Here, we identified small-molecule inhibitors of Wnt antagonist Dkk through molecular modeling, computation-based virtual screens, and biological assays. One of the Dkk inhibitors reduced basal blood-glucose concentrations and improved glucose tolerance in mice. This Dkk inhibitor appeared to act through DKK2 because the inhibitor exerted no additional effects on glucose metabolism in the Dkk2~(-/-) mice. Our study of Dkk2~(-/-) mice showed that DKK2 deficiency was associated with increased hepatic glyco-gen accumulation and decreased hepatic glucose output. DKK2 deficiency did not cause in increase in insulin production but resulted in increased Wnt activity and GLP1 production in the intestines. Given that the Dkk inhibitor improved glucose tolerance in a murine model of type 2 diabetes (dbldb), we suggest that DKK2 may be a potential therapeutic target for treating type 2 diabetes.
机译:Wnt受体LRP5 / 6的突变和Wnt调控的转录因子TCF7L2的多态性与葡萄糖代谢异常有关。但是,尚不清楚Wnt拮抗剂Dickkopf(Dkk)是否在调节葡萄糖代谢中起重要作用。在这里,我们通过分子建模,基于计算的虚拟屏幕和生物学分析确定了Wnt拮抗剂Dkk的小分子抑制剂。 Dkk抑制剂之一可降低小鼠的基础血糖浓度并改善葡萄糖耐量。该Dkk抑制剂似乎通过DKK2起作用,因为该抑制剂对Dkk2〜(-/-)小鼠的葡萄糖代谢没有其他影响。我们对Dkk2〜(-/-)小鼠的研究表明DKK2缺乏与肝糖原积累增加和肝葡萄糖输出减少有关。 DKK2缺乏症不会导致胰岛素产生增加,但会导致肠内Wnt活性和GLP1产生增加。鉴于Dkk抑制剂改善了2型糖尿病鼠模型(dbldb)的葡萄糖耐量,我们建议DKK2可能是治疗2型糖尿病的潜在治疗靶标。

著录项

  • 来源
  • 作者单位

    Department of Pharmacology and Vascular Biology and Therapeutic Program,Yale School of Medicine, New Haven, CT 06520 Enzo Therapeutics, Farmingdale, NY 10022;

    Department of Structural Biology, St. Jude Hospital,Memphis, TN 38105;

    Department of Pharmacology and Vascular Biology and Therapeutic Program,Yale School of Medicine, New Haven, CT 06520;

    Department of Pharmacology and Vascular Biology and Therapeutic Program,Yale School of Medicine, New Haven, CT 06520;

    Department of Structural Biology, St. Jude Hospital,Memphis, TN 38105;

    Department of Structural Biology, St. Jude Hospital,Memphis, TN 38105;

    Department of Structural Biology, St. Jude Hospital,Memphis, TN 38105;

    Department of Internal Medicine,Yale School of Medicine, New Haven, CT 06520 Veteran's Administration Medical Center, West Haven, CT 06516;

    Department of Internal Medicine,Yale School of Medicine, New Haven, CT 06520 Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06520;

    Enzo Therapeutics, Farmingdale, NY 10022;

    Department of Structural Biology, St. Jude Hospital,Memphis, TN 38105;

    Department of Pharmacology and Vascular Biology and Therapeutic Program,Yale School of Medicine, New Haven, CT 06520;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    signal transduction;

    机译:信号转导;
  • 入库时间 2022-08-18 00:40:25

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号